Modern MES Drives High-Throughput, High-Quality CDMO Manufacturing

Contract development and manufacturing organizations (CDMOs) operate multiproduct facilities and support a wide range of customers, timelines, and project requirements. As such, it is critical that their operations remain flexible enough to handle frequent change while still meeting the stringent regulatory expectations that govern drug development and commercial production. Achieving both agility and reliable compliance has become increasingly difficult as CDMOs take on more products, more modalities, and more sponsors, often with very different expectations for documentation, reporting, and process oversight.

Many current manufacturing execution systems (MES) complicate this reality. Traditional MES platforms are built around fixed configurations that are difficult to modify. As a result, they rarely match the level of variability that CDMOs must manage every day. Adapting an off-the-shelf MES usually requires extensive configuration work before it can support routine operations, and those customizations introduce cost, complexity, and long-term rigidity. Purpose-built systems can be just as inflexible. Once deployed, even minor changes often require a specialist or vendor intervention, slowing down the organization and making continuous improvement harder than it should be.

Older MES platforms were primarily designed to manage execution on the production floor, and while many support integrations with equipment and asset management systems, connections to other critical digital environments are often less mature. Integration with quality, training, supplier oversight, and document management systems can require custom work or middleware, which slows down change and creates friction during execution and review. When these systems operate in isolation, information that should be synchronized across functions — such as training status, controlled documents, or supplier changes — must be reconciled manually. This increases workload for operators and quality teams, and can delay batch release when discrepancies or missing records surface late in the process.

Compounding the issue is the persistent reliance on paper-based and PDF-based communication between CDMOs and their customers. Even when point solutions like DocuSign are used for signatures, static PDF files are still circulated by email throughout the workflow. Batch records, specifications, change requests, and approvals often move back and forth as attachments, with limited real-time visibility into status or bottlenecks. For CDMOs managing dozens of clients — each with its own documentation formats and approval chains — these disconnected processes can delay resolutions, extend review cycles, and reduce overall responsiveness.

As outsourcing evolves and sponsor expectations rise, CDMOs need digital processes that can scale with their portfolios. Managing a few PDF-driven workflows may be workable for a small operation, but it becomes unsustainable as customer counts climb and regulatory complexity increases. Digitalization is no longer simply an efficiency upgrade; it is quickly becoming a prerequisite for meeting global regulatory demands, maintaining data integrity, and demonstrating the operational maturity that sponsors now expect when selecting long-term manufacturing partners. Paper-based processes and disconnected systems leave organizations exposed to compliance risk, slower batch release, and diminished competitiveness — pressures that only intensify as the industry moves toward more specialized therapies.

An effective compliance strategy for CDMOs begins with an MES that is both fit for purpose and flexible enough to support the volatility inherent in contract manufacturing. A system designed for this environment should replace the manual processes that introduce the greatest regulatory risk — especially those involving documentation, signoffs, and operator-driven variability — with digital workflows that align with multiple regulatory frameworks simultaneously. It should also offer a deployment timeline measured in months rather than years. Older systems often require one to two years of implementation including customization and validation before they are usable. In contrast, a modern MES should allow rapid implementation, support risk-based validation, and evolve in step with emerging artificial intelligence (AI) standards and regulatory expectations.

MasterControl’s lighter, purpose-built MES, Manufacturing Excellence (Mx), is designed with these requirements in mind. Its 3- to 6-month implementation window allows CDMOs to adopt digital execution without the lengthy configuration cycles associated with legacy platforms. The system supports U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and other global regulatory frameworks out of the box and includes tools that streamline technology transfer for client projects, standardize workflows across sites, and scale templates for new products or facilities. These capabilities give teams earlier visibility into risks and reduce the manual burden associated with routine review tasks. The platform’s validation strategy follows a modern, risk-based approach that aligns with current FDA and global authority expectations and simplifies ongoing upgrades.

A key advantage of MasterControl’s MES is the Builder Tool, a no-code configuration environment that allows users to create and adjust workflows and recipes without specialized technical skills. Teams can build digital processes by selecting steps, dragging elements into place, and embedding images or videos to support operator guidance. Dependencies and hierarchies can be defined through the same interface. This approach preserves flexibility for CDMOs — who often need to update instructions quickly as customer or regulatory requirements evolve — while still enforcing the structure and controls required for compliant execution.

MasterControl’s Mx supports digitization and standardization of core manufacturing processes, including cleaning validation and verification, recipe management, batch record version control, operator training checks, equipment readiness reviews, and change control and deviation documentation. Real-time checklists, automated alerts, and role-based workflows ensure that every step is completed accurately and captured within the audit trail. These capabilities make changeovers more repeatable and efficient while maintaining full traceability and compliance.

Quality is reinforced through seamless integration between Mx and MasterControl’s quality management system (QMS). Pre-configured digital templates reduce variability, role-based access controls maintain data integrity, embedded checks identify deviations earlier in the process, and real-time dashboards support proactive oversight. Together, these features help CDMOs maintain consistent execution while scaling to meet new customer, regulatory, and product demands.

The MasterControl cloud-based MES for biomanufacturing goes well beyond helping CDMOs satisfy regulatory expectations. It strengthens traceability, enhances responsiveness, and supports consistent execution across the entire operation. The goal is to give contract manufacturers a scalable digital foundation that supports operational excellence by enabling structured, repeatable strategies for building batch recipes, managing documentation, and defining process logic as their project portfolios expand.

The system includes tools that allow users to create foundational templates that can serve as the basis for multiple products or clients. Additional recipes, variations, and workflows can then be added without rebuilding entire processes from scratch. This allows experience gained on one project to be carried forward to others, improving standardization and reducing onboarding time for new products. During MES configuration, many CDMOs use this opportunity to reassess their existing documentation and regulatory practices, strengthen controls, and eliminate unnecessary steps that accumulated over time. The result is improved consistency, clearer governance, and more efficient workflows across programs.

The system’s high degree of configurability also gives customers multiple ways to solve a single operational problem. This flexibility often becomes a practical guide during implementation. By walking through different configuration options, teams gain a deeper understanding of their own processes and can align them more closely with compliance expectations and best practices. Once the system is deployed, MasterControl conducts ongoing check-ins to help customers expand functionality, refine workflows, and onboard new clients independently. Over time, CDMOs gain the capability to configure and extend the environment themselves, eliminating their reliance on external specialists and ensuring that digital maturity continues to grow in parallel with the business.

AI, machine learning (ML), natural language processing (NLP), and other advanced digital technologies have significant potential to increase both the efficiency and compliance of biomanufacturing operations. However, that potential can only be realized in facilities that have begun or completed a meaningful digital transformation. Once core processes are digitized and structured data are available, AI becomes a powerful enabler across multiple functions, particularly in regulatory intelligence, batch analysis, document generation, and process optimization.

MasterControl has developed several AI-driven capabilities that support these use cases. One example is Regulatory Chat, a tool powered by generative AI that allows users to interact directly with continually updated global regulations. By searching, querying, or validating against regulatory text, teams can confirm that documents, workflows, and records created within the system align with applicable requirements. This reduces the manual burden of regulatory interpretation and provides real-time guidance during design, review, and execution of GMP activities.

AI also plays a role in improving collaboration between CDMOs and their customers. MasterControl has introduced tools that generate real-time batch summaries, giving sponsors immediate visibility into production status without relying on static reports or manual updates. Near-term enhancements are focused on expanding these capabilities so that deviations, exceptions, and key metrics can be surfaced earlier and with greater context.

Over the longer term, MasterControl is building AI-enabled batch analysis into the MES itself. By analyzing large volumes of batch data across extended time periods, the system will be able to identify patterns, highlight sources of variability, and recommend process changes that drive improved outcomes. This type of analysis has historically required labor-intensive review cycles; automation will make it both faster and more comprehensive.

Finally, MasterControl is applying AI to one of the most time-consuming tasks for CDMOs: onboarding new clients. The technology will make it possible to generate electronic versions of paper batch records automatically, reducing manual transcription and accelerating the transition from customer documentation to fully digital execution. This future capability will help CDMOs scale their operations more efficiently while reducing the risk of errors during onboarding.

Partnering to Shape the MES of the Future

MasterControl is an active member of BioPhorum, a global collaboration network that brings together biopharmaceutical companies, technology providers, and industry experts to advance manufacturing and quality practices. Through BioPhorum’s structured workstreams, members share insights, test emerging ideas, and help shape best practices that accelerate progress across the industry.

One of these workstreams focuses on the evolution of MES. As part of this group, MasterControl collaborated with fellow vendors and manufacturers to develop the MES of the Future manifesto. The document outlines a vision for next-generation MES architectures designed to overcome the limitations of today’s systems, including poor configurability, long time-to-value, and high life cycle costs. The manifesto calls for flexible, modular, cloud-ready solutions that support rapid change, seamless integration, and efficient validation — principles that align closely with the digital transformation needs of CDMOs and other high-mix manufacturing environments.

Many MES vendors are attempting to address the limitations of traditional systems, but few bring decades of experience supporting biomanufacturing across a fully connected platform ecosystem. MasterControl’s cloud-based MES integrates natively with the company’s long-standing QMS, which today supports more than 1,200 customers. Quality and manufacturing intersect at numerous points, from controlled documents and training verification to deviation handling, batch holds, and release readiness. MasterControl has built intentional integration points across these activities, enabling document linking, automated training checks, direct deviation generation from the MES, and batch release controls tied to quality events. These capabilities reduce manual effort, ensure consistency, and create a seamless experience for operators and quality teams.

MasterControl has also expanded its connected platform with Asset Excellence (Ax), a recently acquired asset management solution. Ax centralizes information about equipment status, maintenance schedules, calibration requirements, and utilization. By ensuring assets receive timely and appropriate servicing, Ax strengthens compliance while reducing downtime and variability across production lines. Integration across all MasterControl platforms will allow equipment readiness to be validated automatically during batch execution, further tightening the connection between operations and quality.

Beyond system integration, MasterControl provides extensive data analysis capabilities that give CDMOs a clearer view of their processes. With unified data flowing across MES, QMS, and asset management, teams can better understand how equipment performance, training status, documentation accuracy, and process execution collectively influence manufacturing outcomes. This level of insight supports more informed decisions, earlier detection of risks, and continuous improvement across programs. When these systems work together, biomanufacturing operations become more predictable, more compliant, and better able to scale.

For today’s CDMOs, digital transformation is no longer limited to achieving regulatory compliance. It has become a driver of business value and a meaningful differentiator in a crowded market. Sponsors increasingly evaluate digital maturity before awarding contracts, since modern tools directly influence operational speed, decision quality, and the reliability of outcomes. Real-time visibility into batch status gives sponsors the transparency they expect from long-term partners. At the same time, CDMOs need digital systems that support rapid pivots, clear oversight, and repeatable execution as product volumes and client portfolios expand.

MasterControl’s Mx solution is built specifically for the operational realities of contract manufacturing and is designed to support agility from day one. It reduces paperwork, connects data streams, accelerates decision-making, and simplifies core compliance tasks. By linking quality, operations, and assets, the platform strengthens collaboration across teams and sites. These capabilities help CDMOs identify bottlenecks sooner, respond to deviations more effectively, and maintain consistent performance as their operations scale.

Key capabilities include:

• Cloud-based access to production and quality data for fully paperless operations

• Automated data capture that reduces errors and speeds batch review

• Real-time deviation management tied directly to batch execution

• Customizable workflows that reflect product-specific and client-specific needs

• Built-in analytics and real-time visibility across manufacturing and quality

• Support for diverse regulatory frameworks

• Risk-based validation aligned with modern regulatory expectations

• Validated equipment integration through connected asset management

• Horizontal scalability across multiple products, customers, and facilities

• AI and ML tools for process optimization, anomaly detection, predictive maintenance, and deeper operational insights

Regulators continue to emphasize supply chain transparency, data integrity, and timely quality oversight, while commercial pressures push biomanufacturers to deliver more with fewer resources. Modern digital infrastructure allows CDMOs to keep pace with these evolving demands by maximizing efficiency without proportional workforce expansion. It also positions them to support the unique requirements of emerging modalities, where smaller batch sizes and greater variability make manual processes especially unsustainable.

Digital transformation is not simply a matter of adopting new tools. It is the foundation for long-term competitiveness and operational resilience. Organizations that embrace paperless execution and AI-ready systems are better equipped to respond to client needs quickly, maintain high standards of quality, and manufacture increasingly complex products at sustainable margins.